09:54 AM EST - Oncolytics Biotech Inc. : Announced preliminary data from a randomized Phase II clinical trial of its lead product, REOLYSIN®, in combination with FOLFOX-6 and bevacizumab (Avastin®) in patients with advanced or metastatic colorectal cancer. Oncolytics Biotech Inc.
shares T.ONC are trading down $0.15 at $0.56.
